Drug Approval | July 23, 2024
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
This transaction is the third acquisition by three different Japanese players in this segment
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
The pooled prevalence of GERD in the Indian population is 15.6 %
The inspection closed with five observations which were more of procedural changes with none of these related to data integrity
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
The Unit has been issued GMP Certification from ANVISA-Brazil
Subscribe To Our Newsletter & Stay Updated
